References
Bone RC (1991) The pathogenesis of sepsis. Ann Intern Med 115:457–469
Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock — Relation to multiple-system organ failure and mortality. Chest 103:565–575
Gotloib L, Barzilay E, Shustak A, Wais Z, Jaichenko J, Lev A (1986) Hemofiltration in septic ARDS. The artificial kidney as an artificial endocrine lung. Resuscitation 13:123–132
Barzilay E, Kessler D, Berlot G, Gullo A, Geber D, Ben Zeev I (1989) Use of extra-corporeal supportive techniques as additional treatment for septic-induced multiple organ failure patients. Crit Care Med 17:634–637
Coraim FJ, Coraim HP, Ebermann R, Stellwag FM (1986) Acute respiratory failure after cardiac surgery: clinical experience with the application of continuous arteriovenous hemofiltration. Crit Care Med 14:714–718
Bagshaw ONT, Anaes FRC, Hutchinson A (1992) Continuous arteriovenous hemofiltration and respiratory function in multiple organ systems failure. Intensive Care Med 18:334–338
DiCarlo JV, Dudley TE, Sherbotie JR, Kaplan BS, Costarino AT (1990) Continuous arteriovenous hemofiltration/dialysis improves pulmonary gas exchange in children with multiple organ system failure. Crit Care Med 18: 822–826
Storck M, Hartl WH, Zimmerer E, Inthorn D (1991) Comparison of pumpdriven and spontaneous continuous hemofiltration in postoperative acute renal failure. Lancet 337:452–455
Staubach KH, Rau HG, Kooistra A, Shardey HM, Hohlbach G, Schildberg FW (1989) Can hemodiafiltration increase survival in acute endotoxemia—a porcine shock model. Prog Clin Biol Res 308:821–826
Gomez A, Wang R, Unruh H, Light RB, Bose D, Chau T, Correa E, Mink S (1990) Hemofiltration reverses left ventricular dysfunction during sepsis in dogs. Anesthesiology 73:671–685
Stein B, Pfenninger E, Grünert A, Schmitz JE, Hudde M (1990) Influence of continuous hemofiltration on hemodynamics and central blood volume in experimental endotoxic shock. Intensive Care Med 16:494–499
Stein B, Pfenninger E, Grünert A, Schmitz JE, Deller A, Kocher F (1991) The consequences of continuous hemofiltration on lung mechanics and extravascular lung water in a porcine endotoxic shock model. Intensive Care Med 17:293–298
Grootendorst AF, Van Bommel EFH, Van der Hoven B, Van Leengoed LAMG, Van Osta ALM (1992) High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig. Intensive Care Med 18:235–240
Hack CE, Thijs LG (1991) The orchestra of mediators in the pathogenesis of septic shock: a review. In: Vincent JL (ed) Update in intensive care and emergency medicine, vol 14, update 1991. Springer, Berlin Heidelberg New York, pp 232–246
Fong Y, Moldawer LL, Shires GT, Lowry SF (1990) The biologic characteristics of cytokines and their implication in surgical injury. Surg Gynecol Obstet 170:363–378
Beutler B (1993) Endotoxin, tumor necrosis factor, and related mediators: new approaches to shock. New Horizons 1:3–12
Shapiro L, Gelfond JA (1993) Cytokines and sepsis: pathophysiology and therapy. New Horizons 1:13–22
Tracey KJ, Cerami A (1993) Tumor necrosis factor: an updated review of its biology. Crit Care Med 21:S415-S422
Dinarello CA, Aiura K, Gelfand JA (1992) The role of interleukin-1 in septic shock. In: Vincent JL (ed) 1992 Yearbook of intensive care and emergency medicine. Springer, Berlin Heidelberg New York, pp 25–35
Lowry SF (1993) Anticytokine therapies in sepsis. New Horizons 1:120–126
Dinarello CA, Gelfand JA, Wolff SM (1993) Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269: 1829–1935
Golper TA, Vincent HH, Gleason JR, Vos MC (1993) Drug removal during high efficiency and high-flux hemodialysis. Contemp Issues Nephrol 27: 175–208
Vincent HH, Akcahuseyin E, Goessens WHF, Van Duyl WA, Schalekamp MADH (1993) Drug clearance by continuous haemodiafiltration (CAVHD). Analysis of sieving coefficient and mass transfer coefficients of diffusion. Blood Purif 11:99–107
Lee CC, Marbury TC (1984) Drug therapy in patients undergoing hemodialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet 9:42–66
Reetze-Bonorden P, Bohler J, Keller E (1993) Drug dosage in patients during continuous renal replacement therapy: pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 24: 162–179
Beutler BA, Milsark IW, Cerami A (1985) Cachectin/tumor necrosis factor: production, distribution and metabolic fate in vivo. J Immunol 135: 3972–3977
Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA, Cerami A, Shires GT, Lowry SF (1988) Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 166:147–153
Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyers S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481–1486
Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, Van der Meer JWM, Endres S, Lonneman G, Corsetti J, Chernow B, Wilmore DW, Wolff SM, Burke JF, Dinarello CA (1990) Circulating Interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79–84
Suffredini AF (1992) Endotoxin administration to humans: a model of inflammatory responses relevant to sepsis. In: Lamy M, Thijs LG (eds) Mediators of sepsis. Update in intensive care and emergency medicine, vol 16. Springer, Berlin Heidelberg New York, pp 13–30
Ertel W, Morrison MH, Wang P, Zheng FB, Ayala A, Chaudry IH (1991) The complex pattern of cytokines in sepsis. Ann Surg 214:141–148
Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P (1989) Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17:975–978
De Groote MA, Martin MA, Densen P, Pfaller MA, Wenzel RP (1989) Plasma tumor necrosis factor levels in patients with presumed sepsis. JAMA 262: 249–251
Marano MA, Fong Y, Moldawer LL, Wei H, Calvano SE, Tracey KJ, Barie PS, Manogue K, Cerami A, Shires GT, Lowry SF (1990) Serum cachectin/tumor necrosis factor in critically ill patients with burns correlated with infection and mortality. Surg Gynecol Obstet 170:32–38
Offner F, Phillipé J, Vogelaers D, Colardyn F, Baele G, Baudrihaye M, Vermeulen A, Leroux-Roels G (1990) Serum tumor necrosis factor levels in patients with infections disease and septic shock. J Lab Clin Med 116:100–105
Munoz C, Misset B, Fitting C, Blériot JP, Carlet J, Cavaillon JM (1991) Dissociation between plasma and monocyte-associated cytokines during sepsis. Eur J Immunol 21:2177–2184
Dofferhoff ASM, Bom VJJ, De Vries-Hospers HG, Van Ingen J, Van der Meer J, Hazenberg BPC, Mulder POM, Weits J (1992) Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 20:185–192
Calandra T, Baumgartner JD, Gran GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP and the Swiss-Dutch J 5 immunoglobulin study group (1990) Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α and interferon-γ in the serum of patients with septic shock. J Infect Dis 161:982–987
Debets JMH, Kampmeijer R, Van der Linden MPMH, Buurman WA, Van der Linden CJ (1989) Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 17: 489–494
Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN (1985) Human tumor necrosis factor: production, purification and characterization. J Biol Chem 260:2345–2354
Smith RA, Baglioni C (1987) The active form of tumor necrosis factor is a trimer. J Biol Chem 262:6951–6954
Wollenberg GK, La Marre J, Rosendal S, Gonias SL, Hayes MA (1991) Binding of tumor necrosis factor alpha to activated forms of human plasma alpha 2 macroglobulin. Am J Pathol 138: 265–272
Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis facxtor α in vitro and in vivo. Proc Natl Acad Sci USA 89:4845–4849
Lantz M, Malik S, Slevin ML, Olsson I (1990) Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in human. Cytokine 2:402–406
Kriegler M, Perez C, DeFay K, Albert I, Lu SD (1988) A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications of the complex physiology of TNF: Cell 53:45–53
Tracey KJ, Cerami A (1992) Tumor necrosis factor and regulation of metabolism in infection: role of systemic versus tissue level. Proc Soc Exp Biol Med 200:233–239
Ginoir BP, Johnson JH, Braun T, Allen GL, Bentler B (1992) The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 90:693–698
Tracey KJ, Morgello S, Koplin B, Fahey TJ, Fox J, Aledo A, Manogue K, Cerami A (1990) Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. J Clin Invest 86:2014–2024
Fong Y, Marano MA, Moldawer LL, Wei H, Calvano SE, Kenney JS, Allison AC, Cerami A, Shires GT, Lowry SF (1990) The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 85:1896–1904
Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starries HF, Sherwin SA, Old LJ, Oettgen HF (1987) Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5:1942–1951
Blick M, Sherwin SA, Rosenblum M, Gutterman J (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47: 2986–2989
Damas P, Ledoux D, Nys M, Vrindts Y, DeGroote D, Franchimont P, Lamy M (1992) Cytokine serum level during severe sepsis: human IL-6 as a marker of severity. Ann Surg 215:356–362
Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock: Association between interleukin-6, interleukin-1 and fatal outcome. J Exp Med 169:333–338
Girardin E, Grau GW, Dayer JM, Roux-Lombard P, the J 5 study group, Lambert PH (1988) Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319:397–400
Bath W, Luger TA (1989) Identification of α 2 macroglobulin cytokine binding plasma protein. Binding of interleukin 1 β α 2 macroglobulin. J Biol Chem 264:5818–5825
Dinarello CA, Thompson RC (1991) Blocking IL-1: Interleukin-1 receptor antagonist in vivo and in vitro. Immunol Today 12:404–409
Kunkel SL, Spengler M, May MA, Spengler R, Larrick J, Remick D (1988) Prostaglandin E-2 regulates macrophage derived tumor necrosis factor gene expression. J Biol Chem 263: 5380–5384
Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A (1986) Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232:977–980
Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA (1990) Correlations and interactions in the production of interleukin-6 (IL-6), interleukin-1 (IL-1) and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75:40–47
Barrera P, Janssen EM, Demacker PNM, Wetzels JFM, Van der Meer JWM (1992) Removal of interleukin-1β and tumor necrosis factor from human plasma by in vitro dialysis with polyacrylonitrile membranes. Lymfokine Cytokine Res 11:99–104
Lonneman G, Koch KM, Shaldon S, Dinarello CA (1988) Studies on the ability of hemodialysis membranes to induce, bind and clear human interleukin-1. J Lab Clin Med 112:76–86
Lonneman G, Schindler R, Dinarello CA, Koch KM (1993) Removal of cytokines by hemodialysis membrane in vitro. In: Faist E, Meakins J, Schildberg FW (eds) Host defense dysfunction in trauma, shock and sepsis. Springer, Berlin Heidelberg New York, pp 613–623
Dinarello CA, Koch KM, Shaldon S (1988) Interleukin-1 and its relevance in patients treated with hemodialysis. Kidney Int 33 [Suppl 24]:S21-S26
Tetta C, Camussi G, Turello E, Salomone M, Aimo G, Priolo G, Segoloni G, Vercellone A (1990) Production of cytokines in hemodialysis. Blood Purif 8:337–346
Lonneman G, Haubitz M, Schindler R (1990) Hemodialysis-associated induction of cytokines. Blood Purif 8: 214–222
Herbelin A, Nguyen AT, Urena P, Descamps-Latscha B (1992) Induction of cytokines by dialysis membranes in normal whole blood: a new in vitro assay for evaluating membrane biocompatibility. Blood Purif 10:40–52
Bigazzi R, Atti M, Baldari B (1990) High-permeable membranes and hypersensitivity-like reactions: role of dialysis fluid contamination. Blood Purifc 8: 190–198
Nagaki M, Hughes RD, Lau JYN, Williams R (1991) Removal of endotoxin and cytokines by adsorbents and the effect of plasma protein binding. Int J Artif Organs 14:43–50
Byrick RJ, Goldstein MB, Wong PY (1982) Increased plasma tumor necrosis factor concentration in severe rhabdomyolysis is not reduced by continuous arteriovenous hemodialysis. Crit Care Med 20:1483–1486
Kierdorf H, Melzer H, Weissen D, Heintz B, Sieberth HG (1992) Elimination of tumor necrosis factor α (TNFα) by continuous venovenous hemofiltration (Abstr). Ren Fail 14:98
McDonald BR, Mehta RL (1989) Transmembrane flux of IL-1β and TNFα in patients undergoing continuous arteriovenous hemodialysis (Abstr). J Am Soc Nephrol 1:56
Bellomo R, Tipping P, Boyce N (1991) Tumor necrosis factor clearance during veno-venolus hemodiafiltration in the critically ill. Trans Am Soc Artif Intern Organs 37:M322–323
Bellomo R, McGrath B, Boyce N (1991) In vivo catecholamine extraction during continuous hemodiafiltration in inotrope-dependent patients. Trans Am Soc Artif Intern Organs 37:M324–325
Lefer AM, Martin J (1970) Origin of myocardial depressant factor in shock. Am J Physiol 218:1423–1427
Parillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W (1985) A circulating myocardial depressant substance in humans with septic shock: Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 76:1539–1553
Reilly JM, Cunnion RE, Burch-Whitman C, Parker MM, Shelhamer JH, Parillo JE (1989) A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock. Chest 95: 1072–1080
Janbon B, Vuillez JP, Carpentier F, Barnoud D, André-Poyand P, Barbe G, Guigniez (1992) Removal of circulating tumor necrosis factor. Its role in septic shock treatment. Ann Méd Interne 143 [Suppl 1]:13–16
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schetz, M., Ferdinande, P., Van den Berghe, G. et al. Removal of pro-inflammatory cytokines with renal replacement therapy: Sense or nonsense?. Intensive Care Med 21, 169–176 (1995). https://doi.org/10.1007/BF01726541
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01726541